Luigi Gugliotta

On the behalf of Fondazione Italiana Linfomi (FIL), Alessandria, Italy, | S. Orsola-Malpighi Hematology-Oncology, University of Bologna, Bologna, Italy, | Department of ...

Essential Thrombocythemia | Rituximab Patients | Imatinib Therapy | Diagnosed Multiple | Primary Immune Thrombocytopenia

KOL Resume for Luigi Gugliotta

Year
2012	On the behalf of Fondazione Italiana Linfomi (FIL), Alessandria, Italy,
2010	S. Orsola-Malpighi Hematology-Oncology, University of Bologna, Bologna, Italy,
2009	Department of Hematology, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy,
2008	Ematologia-Reggio Emilia, Italy
2005	Division of Hematology, Reggio Emilia, Italy
2004	Hematology, Hosp.S.Maria Nuova, Reggio Emilia, Italy

Prominent publications by Luigi Gugliotta

Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis o

[ PUBLICATION ]

KOL-Index: 5816

BACKGROUND: The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the triplet regimen over the doublet in terms of increased complete response rate and improved progression-free survival. We report ...

Known for Multiple Myeloma | Cell Transplantation | Induction Therapy | Triplet Regimen | Bortezomib Dexamethasone

Key People For Essential Thrombocythemia

Top KOLs in the world

Tefferi Tefferi

essential thrombocythemia primary myelofibrosis polycythemia vera

Tiziano Barbui

polycythemia vera essential thrombocythemia myeloproliferative neoplasms

Guido Finazzi

polycythemia vera essential thrombocythemia myeloproliferative neoplasms

Alessandro Maria Vannucchi

speakers bureau board directors polycythemia vera

Claire N Harrison

speakers bureau board directors advisory committees

Francesco Passamonti

speakers bureau polycythemia vera board directors

Select a search phrase essential thrombocythemia , essential thrombocythemia vera , essential thrombocythemia jak2 , essential thrombocythemia pmf , essential thrombocythemia mpns

Luigi Gugliotta:Expert Impact

Concepts for whichLuigi Gugliottahas direct influence:Essential thrombocythemia, Rituximab patients, Rituximab itp, Imatinib therapy, Patients itp, Diagnosed multiple, Primary immune thrombocytopenia, Itp patients.

Luigi Gugliotta:KOL impact

Concepts related to the work of other authors for whichfor which Luigi Gugliotta has influence:Multiple myeloma, Immune thrombocytopenia, Postprotocol therapies, Eosinophilic disorders, Minimal residual disease, Patients rituximab, Idecabtagene vicleucel.

Tools

Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile https://www.keyopinionleaders.com/Essential-Thrombocythemia/Luigi-Gugliotta-On-The-Behalf-Of-Fondazione-Italiana-Lin-18c5d1590e47e84b5d1a116520db2c83-zf.html

On the behalf of Fondazione Italiana Linfomi (FIL), Alessandria, Italy, | S. Orsola-Malpighi Hematology-Oncology, University of Bologna, Bologna, Italy, | Department of Hematology, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, | Ematologia-Reg